Lymphoma Clinical Trials

Showing 1941-1960 of 3,379 trials

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

NCT03837457

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype in subjects who have confirmed disease progression following treatment with vorinostat in the SOLAR clinical study (MRG106-11-201). Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects.

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

miRagen Therapeutics, Inc.8 participantsStarted Oct 2019

Phoenix, Arizona, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +6 more locations

UNKNOWNPhase 2

Biomarker Guided Treatment in DLBCL

NCT04025593

This study is to investigate the strategy of biomarker guided treatment in diffuse large B cell lymphoma

Diffuse Large B Cell Lymphoma

Ruijin Hospital128 participantsStarted Jul 2019

Shanghai, Shanghai Municipality, China

PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study

Biomarker Guided Treatment in DLBCL

Related Searches

Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

HD16 for Early Stage Hodgkin Lymphoma

Rehabilitation Needs of the Malaysian Haematological Cancer Survivors

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma

The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)